6. Mai 2013, Oberlandesgericht München: Im Saal A 101 beginnt der Prozess gegen die Hauptangeklagte Beate Zschäpe und vier Mitangeklagte. Es ist das größte Rechtsterrorismusverfahren der deutschen Ges...

Aardvark Therapeutics, Inc. is facing a securities class action lawsuit regarding safety claims of ARD-101. Investors urged to respond by October 13, 2026.

A pending securities class action against Aardvark Therapeutics raises questions about the safety and regulatory prospects of their drug ARD-101 and its impact on investors.

6. Mai 2013, Oberlandesgericht München: Im Saal A 101 beginnt der Prozess gegen die Hauptangeklagte Beate Zschäpe und vier Mitangeklagte. Es ist das größte Rechtsterrorismusverfahren der deutschen Ges...

6. Mai 2013, Oberlandesgericht München: Im Saal A 101 beginnt der Prozess gegen die Hauptangeklagte Beate Zschäpe und vier Mitangeklagte. Es ist das größte Rechtsterrorismusverfahren der deutschen Ges...

Investors in Aardvark Therapeutics, Inc. have an opportunity to lead a class action lawsuit due to significant losses before the October 13, 2026 deadline.

Robbins LLP reminds Aardvark Therapeutics, Inc. investors of a class action lawsuit with a deadline of October 13, 2026 for lead plaintiff applications, due to alleged misrepresentation.

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

Das sind unsere Themen diese Woche: - Tagesschauposts mit den meisten Interaktionen (00:01:29) Demos für Lorenz A. Papst beigesetzt Kind beschädigt 50-Millionen

YouTube video by AI: Reset To Zero

...'on the fly' AI in White House post 'AI Czar' David Sacks

Pomerantz LLP has initiated a class action lawsuit against Aardvark Therapeutics and its officers for misleading investors about company operations and financial prospects.

Obesity management has limited oral pharmacotherapies. Bitter taste receptor (TAS2R) agonists may modulate hunger, satiety, and metabolism via gut-bra…

Investigative Inhalte der ARD - aufwändig recherchierte B...

Hagens Berman announces a securities class action against Aardvark Therapeutics for alleged misrepresentation regarding the safety of ARD-101.

Aardvark Therapeutics (Nasdaq: AARD) reported second quarter 2026 results and pipeline updates, centered on ARD-101 for Prader-Willi syndrome (PWS). The company is assessing unblinded Phase 3 HERO and OLE data in the third quarter of 2026 to evaluate overall efficacy and safety and inform next steps, while remaining in active discussions with the FDA to resolve the full clinical hold on the ARD-101 IND.The HERO and OLE trials were terminated in June 2026 and are not expected to resume as previously designed. As of June 30, 2026, Aardvark held $73.9 million in cash, cash equivalents and short-term investments, which it expects to fund operations into late 2027. Second quarter 2026 R&D expenses were $10.5 million (down from $13.1 million a year earlier), G&A expenses were $4.6 million (up from $2.7 million), and net loss was $14.4 million, roughly unchanged from the prior-year quarter.

Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity

Aardvark Therapeutics investors with significant losses are urged to act before the October 13 deadline for potential class action involvement.

A class action lawsuit has been filed against Aardvark Therapeutics, alleging misleading statements about ARD-101. Investors may be eligible for restitution.

A class action lawsuit has been initiated against Aardvark Therapeutics by Pomerantz Law Firm, alleging misleading statements during the IPO process. Investors are urged to join.